MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 3, 2015, Pages 111.e17-111.e26

  Sun, Dingqi ^a,b   Sawada, Atsuro ^a   Nakashima, Masakazu ^a   Kobayashi, Takashi ^a   Ogawa, Osamu ^a   Matsui, Yoshiyuki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Akt pathway; Cisplatin; Invasion; MK2206; Urothelial cancer

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; PROTEIN BAX; PROTEIN KINASE B; SURVIVIN; TRANSCRIPTION FACTOR ZEB1; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER CELL LINE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; IN VITRO STUDY; INCUBATION TIME; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL MOTION; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE; UROTHELIUM;

ALLOSTERIC SITE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG SYNERGISM; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84925371173     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.10.018     Document Type: Article

References (34)

1. Nishiyama H., Habuchi T., Watanabe J., et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol 2004, 45:176-181.
2. Bellacosa A., Testa J.R., Staal S.P., et al. A retroviral oncogene, Akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991, 254:274-277.
3. Burgering B.M., Coffer P.J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
4. Datta S.R., Brunet A., Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 1999, 13:2905-2927.
5. Nogueira V., Park Y., Chen C.C., et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008, 14:458-470.
6. Pastukh V., Ricci C., Solodushko V., et al. Contribution of the PI3-kinase/Akt survival pathway toward osmotic preconditioning. Mol Cell Biochem 2005, 269:59-67.
7. Mullonkal C.J., Toledo-Pereyra L.H. Akt in ischemia and reperfusion. J Invest Surg 2007, 20:195-203.
8. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002, 5:234-248.
9. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 2002, 14:381-395.
10. Sun C.H., Chang Y.H., Pan C.C. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011, 58:1054-1063.
11. Knowles M.A., Platt F.M., Ross R.L., et al. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009, 28:305-316.
12. Winograd-Katz S.E., Levitzki A. Cisplatin induces PKB/Akt activation and p38 MAPK phosphorylation of the EGF receptor. Oncogene 2006, 25:7381-7390.
13. Bellacosa A., Kumar C.C., Di Cristofano A., et al. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005, 94:29-86.
14. Brognard J., Clark A.S., Ni Y., et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986-3997.
15. Yang X., Fraser M., Moll U.M., et al. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006, 66:3126-3136.
16. Liu L.Z., Zhou X.D., Qian G., et al. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007, 67:6325-6332.
17. Sangai T., Akcakanat A., Chen H., et al. Biomarkers of response to Akt inhibitor MK2206 in breast cancer. Clin Cancer Res 2012, 18:5816-5828.
18. Hirai H., Sootome H., Nakatsuru Y., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9:1956-1967.
19. Ou D.L., Lee B.S., Lin L.I., et al. Vertical blockade of the IGFR-PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin. Mol Cancer 2014, 13:2.
20. Grabomski N., Ewald F., Hofmann B.T., et al. Combined targeting of Akt and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012, 11:85.
21. Cheng Y., Zhang Y., Zhang L., et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012, 11:154-164.
22. Matsui Y., Watanabe J., Ikegawa M., et al. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene 2008, 27:4603-4614.
23. Altomare D.A., Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
24. Jones P.F., Jakubowicz T., Pitossi F.J., et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A 1991, 88:4171-4175.
25. Dahia P.L., Aguiar R.C., Alberta J., et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999, 8:185-193.
26. Tsuruta H., Kishimoto H., Sasaki T., et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN Protein in human bladder cancer patients. Cancer Res 2006, 66:8389-8396.
27. Ma B.B., Liu V.W., Hui C.W., et al. Preclinical evaluation of the Akt inhibitor MK2206 in nasopharyngeal carcinoma cell lines. Invest New Drugs 2013, 31:567-575.
28. Jin R., Nakada M., Teng L., et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett 2013, 534:316-321.
29. Yin T., Wang C., Liu T., et al. Expression of Snail in pancreatic cancer promotes metastasis and chemoresistance. J Surg Res 2007, 141:196-203.
30. Siebzehnrubi F.A., Silver D.J., Tuqertimur B., et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 2013, 5:1196-1212.
31. Ren J., Chen Y., Song H., et al. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. J Cell Biochem 2013, 114:1395-1403.
32. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7:606-619.
33. Ge J., Liu Y., Li Q., et al. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomed Environ Sci 2013, 26:902-911.
34. Shrivastava S., kulkarni P., Thummuri D., et al. Piperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells. Apoptosis 2014, 19:1148-1164.